Leading CRO Ecron Acunova to get re-branded as Navitas Life Sciences

The unified Navitas Life Sciences will help in the consolidation of both infrastructure and operational capabilities of the existing entities and serve as an end-to-end strategic partner for clinical research requirements in India

0
1424
Download PDF
Bengaluru: Ecron Acunova (EA), a fully owned subsidiary of TAKE Solutions and a globally recognized full service CRO with Clinical and BA/BE expertise, has announced that it would be consolidating its capabilities with TAKE’s niche Life Sciences brand Navitas and Intelent to form a unified go-to-market entity – Navitas Life Sciences.
EA’s significant Clinical capabilities, having conducted over 1300 studies including BA/BE, NIS, and phase II – IV in its state-of-the-art and audited facilities, will be augmented by legacy brands Navitas’s technology led solutions across Clinical, Regulatory and Safety, and Intelent’s big data and analytics expertise to form the 360 degree service provider Navitas Life Sciences. The unified Navitas Life Sciences will serve as an end-to-end strategic partner for Life Sciences companies to help them address their critical challenges and achieve their desired outcomes.
The Chennai-based life sciences technology provider, Take Solutions, had stepped deeper into life sciences technology during 2015, with the acquisition of Bengaluru-based Ecron Acunova in an all-cash Rs 115-crore deal.
The Manipal Group and US-based PE fund OrbiMed, the owners at that time had exited Ecron through the deal. Orginally, the Ecron Akunova was an Indo-German collaborative effort. The Manipal Group’s Manipal Acunova had acquired Germany-based Ecron in 2007 to form Ecron Acunova, a clinical research organisation. It has facilities in Bengaluru, Mangalore and Manipal and a lot of access to Manipal’s hospitals.

The unified Navitas Life Sciences will serve as an end-to-end strategic partner for Life Sciences companies to help them address their critical challenges and achieve their desired outcomes.

In her comments on the latest development, Marty Boom, Managing Director, Ecron Acunova, said, “Capitalizing on the phenomenal growth opportunities in the Life Sciences industry calls for diverse capabilities. The unification of Ecron Acunova, Navitas and Intelent will enable a seamless consolidation of capabilities in the form of Navitas Life Sciences, which will enable us to offer clients a full-service coverage of the Pharma and Biotech R&D market.”
Talking about the new avatar, Ram Yeleswarapu, President and CEO, TAKE Solutions, said,We are proud to bring together our substantial and niche capabilities under the unified ambit of Navitas Life Sciences to present our client with truly transformational, flexible and adaptable end-to-end offerings. In addition to our technology driven offerings and insights derived from our world-class proprietary industry networks, our clients now also be able to benefit from the consolidated brand’s proven clinical capabilities and trial experiences.”
Navitas Life Sciences, a wholly owned subsidiary of Take Solutions, works as a strategic partner for large and mid-sized life sciences companies to address critical challenges and achieve desired outcomes.